CoChat

Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)

Open access
Shen, Tong, Kuang, Ye-Hong, Ashby, Charles R., Lei, Yu, Chen, Angel, Zhou, Ying, Chen, Xiang, Tiwari, Amit K., Hopper-Borge, Elizabeth, Ouyang, Jiangyong, Chen, Zhe-Sheng · 2009 · PLoS ONE
Cited by 70

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: One of the major mechanisms that could produce resistance to antineoplastic drugs in cancer cells is the ATP binding cassette (ABC) transporters. The ABC transporters can significantly decrease the intracellular concentration of antineoplastic drugs by increasing their efflux, thereby lowering the cytotoxic activity of antineoplastic drugs. One of these transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to antineoplastic drugs by increasing the efflux of paclitaxel. In this study, we examined the effects of BCR-Abl tyrosine kinase inhibitors imatinib, nilotinib and dasatinib on the activity and expression of MRP7 in HEK293 cells transfected with MRP7, designated HEK-MRP7-2. METHODOLOGY AND/OR PRINCIPAL FINDINGS: We report for the first time that imatinib and nilotinib reversed MRP7-mediated multidrug resistance. Our MTT assay results indicated that MRP7 expression in HEK-MRP7-2 cells was not significantly altered by incubation with 5 microM of imatinib or nilotinib for up to 72 hours. In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine. Imatinib and nilotinib, at 5 microM, significantly increased the accumulation of [(3)H]-paclitaxel in HEK-MRP7-2 cells. The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 microM) also significantly inhibited the efflux of paclitaxel. CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7. These findings suggest that imatinib or nilotinib, in combination with other antineoplastic drugs, may be useful in the treatment of certain resistant cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0007520

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 23

  1. A Jemal, 2008, Cancer statistics., CA Cancer J Clin, 58, 71
  2. CP Wu, 2008, Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies., Curr Mol Pharmacol, 1(2), 93
  3. PA Bradbury, 2004, DNA repair pathways in drug resistance in melanoma., Anticancer Drugs, 15(5), 421, 10.1097/01.cad.0000127665.74096.93 · DOI
  4. MI Borges-Walmsley, 2003, Structure and function of efflux pumps that confer resistance to drugs., Biochem J, 376(Pt 2), 313, 10.1042/bj20020957 · DOI · Paper page
  5. H Naramoto, 2007, Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines., Int J Oncol, 30(2), 393
  6. E Hopper-Borge, 2004, Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel., Cancer Res, 64, 4927, 10.1158/0008-5472.CAN-03-3111 · DOI · Paper page
  7. E Hopper-Borge, 2009, Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B., Cancer Res, 69(1), 178, 10.1158/0008-5472.CAN-08-1420 · DOI
  8. Y Zhou, 2009, Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance., Biochem Pharmacol, 77, 993, 10.1016/j.bcp.2008.12.005 · DOI
  9. Z Shi, 2007, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance., Cancer Res, 67(22), 11012, 10.1158/0008-5472.CAN-07-2686 · DOI · Paper page
  10. AK Tiwari, 2009, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXP transporters., Biochem Pharmacol, 78(2), 153, 10.1016/j.bcp.2009.04.002 · DOI · Paper page
  11. J Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer., J Clin Oncol, 21(14), 2787, 10.1200/JCO.2003.01.504 · DOI · Paper page
  12. S Hirota, 1998, Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors., Science, 279, 577, 10.1126/science.279.5350.577 · DOI · Paper page
  13. NP Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia., Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X · DOI · Paper page
  14. NE Jordanides, 2006, Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate., Blood, 108(4), 1370, 10.1182/blood-2006-02-003145 · DOI · Paper page
  15. MM Schittenhelm, 2006, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies., Cancer Res, 66(1), 473, 10.1158/0008-5472.CAN-05-2050 · DOI · Paper page
  16. DK Hiwase, 2008, Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications., Clin Cancer Res, 14(12), 3881, 10.1158/1078-0432.CCR-07-5095 · DOI · Paper page
  17. J Gora-Tybor, 2008, Targeted drugs in chronic myeloid leukemia., Curr Med Chem, 15(29), 3036, 10.2174/092986708786848578 · doi:10.2174/092986708786848578
  18. S Akiyama, 1985, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs., Somat Cell Mol Genet, 11(2), 117, 10.1007/BF01534700 · DOI · Paper page
  19. T Sumizawa, 1997, Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P., Mol Pharmacol, 51(3), 399, 10.1016/S0026-895X(24)13480-3 · DOI
  20. MM Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding., Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 · DOI · Paper page
  21. L Couture, 2006, The ATP-bind cassette transporters and their implications in drug disposition: a special look at the heart., Pharmacol Rev, 58(2), 244, 10.1124/pr.58.2.7 · DOI
  22. H Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL., New Eng J Med, 354(24), 2542, 10.1056/NEJMoa055104 · DOI · Paper page
  23. C Tanaka, Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib., Clin Pharmacol Ther

Cited by

See all 70

Metadata

Authors
Shen, T., Kuang, Y.-H., Ashby, C. R., Lei, Y., Chen, A., Zhou, Y., Chen, X., Tiwari, A. K., Hopper-Borge, E., Ouyang, J., & Chen, Z.-S.
Venue
PLoS ONE
Published
2009-10-20
Volume
4
Issue
10
Pages
e7520
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1965816291
Cited by
70
References
3
FWCI
3.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). https://app.cochat.ai/papers/10.1371/journal.pone.0007520
The paper
Shen, T., Kuang, Y.-H., Ashby, C. R., Lei, Y., Chen, A., Zhou, Y., Chen, X., Tiwari, A. K., Hopper-Borge, E., Ouyang, J., & Chen, Z.-S. (2009). Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS ONE. https://doi.org/10.1371/journal.pone.0007520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.